Repositive makes world-leading directory of 5,300 preclinical cancer models publicly browsable as first stage of platform relaunch
Repositive, the Cambridge-based startup that connects researchers with the right preclinical cancer models to enhance their drug development programmes, has made its world-leading directory of preclinical cancer models publicly browsable as the first stage of relaunching its Cancer Models Platform. Accessible via the Repositive website, the online directory lets pharma, biotech and academic researchers browse the metadata of 5,300 cancer models from its CRO partners and easily request access to supporting data to ensure they source models that will be more predictive of patient response, helping to accelerate potentially life-saving cancer therapies to the clinic.
Repositive’s new Cancer Models Platform public listing can be accessed here: https://bit.ly/2xseKPy
With drug development advancing towards an era of precision cancer medicine, pharma and biotech researchers need to source preclinical models with precise molecular and genomic profiles, which has previously been a difficult and task-consuming task. To address this, Repositive has partnered with 18 industry-leading and specialist CROs across the globe to create the world’s largest directory of preclinical cancer models. Via its expert, tailored and confidential Cancer Models Scout service, Repositive is helping researchers access high-quality models with the characteristics they need to provide more robust evidence to support their drug development programmes.
After building the world’s largest directory of preclinical cancer models, Repositive is now relaunching its online marketplace, known as the Cancer Models Platform, for finding and comparing cancer models from different providers. For the first stage of the platform’s relaunch, Repositive has made 5,300 preclinical cancer models from its CRO partner network browsable to help pharma, biotech and academic researchers quickly source the models they need to accelerate the development of novel cancer therapies to patients.
Repositive’s free online directory enables scientists to easily search by tumour location for patient-derived and cell line-derived xenograft models, syngeneic and humanised mouse models, cell lines and organoids. On selecting a tumour location, researchers can view the list of models available from different preclinical oncology CROs around the world, including metadata detailing the model’s primary site, subtype and tumour origin. With model validation being an important requirement when selecting a preclinical cancer model, the new online directory also enables researchers to see what additional data is available for each model, such as genomic, drug response and growth curve data to ensure they identify a model that will be more predictive of clinical response.
Once a model of interest has been identified through the online directory, researchers can simply get in touch with Repositive’s molecular biology and bioinformatics experts via an online form to request more information or request access to supporting data. Through its confidential Cancer Models Scout service, Repositive can provide additional data requested, conduct more in-depth genomic and molecular queries of models if required and introduce researchers to their chosen CRO(s) for further discussion and project planning.
“As part of our commitment to providing scientists with access to the data they need to advance biomedical research, we’re proud to have made our directory publicly browsable via the Repositive website,” said Fiona Nielsen, CEO of Repositive. “Our new Cancer Models Platform will enable pharma and biotech researchers to find models they’ve been struggling to source, discover alternative models that might be better suited to their experiment and explore some of the latest models and technologies on offer. This is the first stage of relaunching our Cancer Models Platform - we’re currently working closely with industry researchers to develop a platform that will best support their preclinical studies and are looking forward to releasing new features and adding more models to the online directory shortly.”
“Our collaboration with Repositive has been a very successful driver of growth for Nexus Pharma and we are excited to expand on it further as we add new PDX models to address unmet medical need,” said Vladimir Khazak, Chief Scientific Officer of Nexus Pharma (now part of Genesis Drug Discovery and Development).
To view Repositive’s new Cancer Models Platform public listing, please visit: https://bit.ly/2xseKPy
